Volume 31, Issue 10 (January 2020)                   Studies in Medical Sciences 2020, 31(10): 792-801 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

URL: http://umj.umsu.ac.ir/article-1-5255-en.html
Department of Parasitology and Mycology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran (Corresponding Author) , arashaminpouir@gmail.com
Abstract:   (2463 Views)
Background & Aims: Toxoplasmosis is one of the most common parasitic infections in humans and other warm-blooded animals. One of the major problems of toxoplasmosis is its therapeutic limitation. The main treatment for this infection is the synergistic combination of pyrimethamine and sulfadiazine, though pyrimethamine is contraindicated in pregnant women owing to its teratogenicity. Considering many side effects that this parasite poses to immunocompromised individuals and pregnant women, the production of anti-Toxoplasma drugs with high efficacy and low side effects is therefore the main objective of Toxoplasma research. The goal of this study was to evaluate the cytotoxic effects of chitosan and ethanolic extract of Dracocephalum kotschyi on Toxoplasma gondii tachyzoites in RH strains under in vitro condition.
Materials & Methods: RH strains of Toxoplasma gondii tachyzoites with the concentrations of 45, 90, and 135 mg / ml of Zarrin-Giah ethanolic extract and concentrations of 150, 300, and 600 mg / ml of chitosan, as well as components of these concentrations were evaluated. They were then compared with the positive control drug (pyrimethamine) and negative control at 24, 48, and 72 hours incubation periods, separately and also by Trypan blue staining and MTT. The lethality percentage of the extract and chitosan was assessed and compared with dead tachyzoites. All stages were evaluated by triple control.
Results: Following 48-hour incubation using Trypan blue test, the concentrations of 135 mg / ml of D. kotschyi, 600 mg / ml of chitosan, and 90 extracts with 150 mg / ml of chitosan were examined. Concentrations of 500 mg / ml of control drug with lethality percentage were 50.9, 77.2, 88.3, and 95.2, and ELISA results of MTT test with ODs of 0.098, 0.087 0.064, and 0.048 showed acceptable results. After 72 hours, more than 80% of toxoplasma tachyzoites were destroyed.
Conclusion: Our findings revealed that chitosan extract, especially its combination with D. kotschyi extract, showed more promising results relative to the positive control drug, pyrimethamine, and the negative control. Moreover, the cytotoxic effects were maximum when these two drugs were used simultaneously.
Full-Text [PDF 508 kb]   (730 Downloads)    
Type of Study: Research | Subject: انگل و قارچ شناسی

1. Ferreira MS, Borges AS. Some aspects of protozoaninfections in immunocompromised patients: areview. Mem Inst Oswaldo Cruz 2002;97(4): 443-57. [DOI:10.1590/S0074-02762002000400001] [PMID]
2. Yazar S, Yaman O, Eser B, Altuntaş F, Kurnaz F,Şahin I. Investigation of Aniti-Toxoplasma gondiiantibodies in patients with neoplasia. Journal ofmedical microbiology 2004; 53(12),1183-6. [DOI:10.1099/jmm.0.45587-0] [PMID]
3. Mostafavi SN, Jalali Monfared L. Toxoplasmosisepidemiology in Iran: a systematic review. J IsfahanMed Sch 2012; 30: 1-15. [URL]
4. Robert-Gangneux F, Dardé ML. Epidemiology ofand diagnostic strategies for toxoplasmosis. ClinMicrobiol Rev 2012; 25(2): 264-96. [DOI:10.1128/CMR.05013-11] [PMID] [PMCID]
5. Dubey J. Toxoplasmosis_a waterborne zoonosis.Vet Parasitol 2004; 126(1): 57-72. [DOI:10.1016/j.vetpar.2004.09.005] [PMID]
6. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet2004; 363:1965-76. [DOI:10.1016/S0140-6736(04)16412-X]
7. Petersen E. Toxoplasmosis. Semin Fetal NeonatalMed 2007; 12: 214-23. [DOI:10.1016/j.siny.2007.01.011] [PMID]
8. Trevor AJ, Katzung BG, Masters SB, Kruidering-Hall M. Pharmacology examination and boardreview. 10th Ed. New York: Mc Graw Hill; 2013. P:451-9. [URL]
9. Zargari A. Medicinal plants, Tehran Universitypublications. Volume 3. 1997, p: 894. [URL]
10. Gupta S, Abu-Ghannam N. Bioactive potential andpossible health effects of edible brown seaweeds.Trends Food Sci Tech 2011;22: 315-26. [DOI:10.1016/j.tifs.2011.03.011]
11. Eisenberg DM. Trends in alter medicine use in theUnited States: results of a follow-up national survey.JAMA 1998;280:1569-75. [DOI:10.1001/jama.280.18.1569] [PMID]
12. Abbasin et al. Evaluation of the antimicrobial effectof Scrophularia spp. On Staphylococcus aureus andPseudomonas aeruginosa and comparison withselective antibodies. Pharmaceutical Journal 2005;Sixth Year - Special Issue 1. (Persian).
13. Barsanti L, et al. biochemistry and biotechnology.New York: Taylor and Francis Group, 2006.
14. Dawczynski C, Schubert R, Jahreis G. Amino acids,fatty acids, and dietary fibre in edible seaweedproducts. Food Chem 2007; 103: 891-9. [DOI:10.1016/j.foodchem.2006.09.041]
15. Zhuang C, Itoh H, Mizuno T, Ito H. Antitumoractive fucoidan from the brown seaweedUmitoranoo. Bios Biotech Biochem 1995;59: 563-7. [DOI:10.1271/bbb.59.563] [PMID]
16. Heo SJ, Park EJ, Lee KW, Jeon YJ. Antioxidantactivities of enzymatic extracts from brownseaweeds. Bioresource Technol 2005; 96: 1613-23. [DOI:10.1016/j.biortech.2004.07.013] [PMID]
17. Kuda T, Tsunekawa M, Goto H, Araki Y.Antioxidant properties of four edible algae harvestedin the Noto Peninsula, Japan. J Food Com Anal2005; 18: 625-33. [DOI:10.1016/j.jfca.2004.06.015]
18. Blanc N, Hauchard D, Audibert L, Gall EA. Radicalscavengingcapacity of phenol fractions in the brownseaweed Ascophyllum nodosum. An electrochemapp 2011; 84: 513-8. [DOI:10.1016/j.talanta.2011.01.034] [PMID]
19. Mary JS, Vinotha P, Pradeep AM. Screening for invitro Cytotoxic Activity of Seaweed, Sargassum sp.Against Hep-2 and MCF-7 Cancer Cell Line. AsianPacific J Cancer Prev 2012; 13 (12): 6073-6 [DOI:10.7314/APJCP.2012.13.12.6073] [PMID]
20. Mohebali M, Rezayat MM, Gilani K, Sarkar S,Akhoundi B, Esmaeili J,et al. Nanosilver in thetreatment of localized cutaneous leishmaniasiscaused by Leishmania major (MRHO/IR/75/ER): anin vitro and in vivo study. DARU: J Pharm Sci 2009;17(4): 285-9. (Persian). [URL]
21. Langer R. Biomaterials in drug delivery and tissueengineering: one laboratory's experience. Acc ChemRes 2000; 33(2): 94-101. [DOI:10.1021/ar9800993] [PMID]
22. Miller CB, Waller EK, Klingemann HG, DignaniMC, Anaissie EJ, Cagnoni PJ, et al. Lipidformulations of amphotericin B preserve andstabilize renal function in HSCT recipients. BoneMarrow Transplant 2004; 33(5): 543-8. [DOI:10.1038/sj.bmt.1704408] [PMID]
23. Jones JL, Hanson DL, Dworkin MS, Alderton DL,Fleming PL, Kaplan JE, et al. Surviellance forAIDS-defining opportunistic illnesses, 1992-1997.Arch Dermatol 1999; 135(8):897-902. [DOI:10.1001/archderm.135.8.897]
24. Tenter AM, Heckeroth AR, Weiss LM. Toxoplasmagondii: from animals to humans. Int J Parasitol 2000;30(12-13):1217-58. [DOI:10.1016/S0020-7519(00)00124-7]
25. Mitchell SM, Zajac AM, Davis WL, Lindsay DS.Efficacy of ponazuril in vitro and in preventing andtreating Toxoplasma gondii infections in mice. JParasitol 2004;90(3): 639-42. [DOI:10.1645/GE-250R] [PMID]
26. Schmidt GD, Roberts LS, Janovy J. Fundations ofParasitology. 7th Ed McGraw-Hill. U.S.; 2005.P.702. [URL]
27. Gupta S. Bioactive potential and possible healtheffects of edible brown seaweeds. Trends Food SciTechnol 2011; 22(6):315-26. [DOI:10.1016/j.tifs.2011.03.011]
28. Heo SJ, Park EJ, Lee KW, Jeon YJ.Antioxidantactivities of enzymatic extracts from brownseawweds. Bioresour technol. 2005; 96(14):161323. [DOI:10.1016/j.biortech.2004.07.013] [PMID]
29. Rechinger H. Flora Ironical, Labiatae,Dracocephalum in flora ironical. Austria:Akademische Druckund Verlagsanstalt., 1986, 150;218-230.
30. Mozaffarian V. A Dictionary of Iranian PlantNames. Tehran: Farhange Moaser; 1996. P.192-3. [URL]
31. Jones-Brando L, D'Angelo J, Posner GH, Yolken R.In vitro inhibition of Toxoplasma gondii by four newderivatives of artemisinin. Antimicrob AgentsChemother 2006; 50: 4206 - 8. [PMID] [PMCID]
32. Kavitha N, Noordin R, Chan KL, Sasidharan S. Invitro anti-Toxoplasma gondii activity of rootextract/fractions of Eurycoma longifolia Jack. BMCComplement Altern Med 2012; 12(1): 91. [DOI:10.1186/1472-6882-12-91] [PMID] [PMCID]
33. Kamali M, Khosroyar S, Mohammadi A.Antibacterial activity of various extracts fromDracocephalum kotschyi against food pathogenicmicroorganisms. lnternational journal of pharmTech 2015; 8(9): 158-63. [URL]
34. Gaafar MR, Mady RF, Diab RG, Shalaby TI.Chitosan and silver nanoparticles: Promising antitoxoplasmaagents. Exp Parasitol 2014; 143: 30-8. [DOI:10.1016/j.exppara.2014.05.005] [PMID]
35. Shagholani H, Ghorbani M, Nikpay A, Soltani M.Chitosan nanocapsule-mounted cellulose nanofibrilsas nanoships for smart drug delivery systems andtreatment of avian trichomoniasis. J Taiwan InstChem Eng 2019;95:290-9. [DOI:10.1016/j.jtice.2018.07.014]
36. Mousavi SA, Ghotaslou R, Kordi S, Khoramdel A,Aeenfar A, Kahjough ST, et al. Antibacterial andAntifungal Effects of Chitosan Nanoparticles onTissue Conditioners of Complete Dentures. Int JBiol Macromol 2018;118:881-5. [DOI:10.1016/j.ijbiomac.2018.06.151] [PMID]
37. Alburquenque C, Bucarey SA, Neira-Carrillo A,Urzúa B, Hermosilla G, Tapia CV. Antifungalactivity of low molecular weight chitosan againstclinical isolates of candida spp. Med Mycol 2010;48(8):1018-23. [DOI:10.3109/13693786.2010.486412] [PMID]
38. Hagras NA, Allam AF, Farag HF, Osman MM,Shalaby TI, Mogahed NM, et al. SuccessfulTreatment of Acute Experimental Toxoplasmosis bySpiramycin-Loaded Chitosan Nanoparticles. ExpParasitol 2019;204:107717. [DOI:10.1016/j.exppara.2019.107717] [PMID]
39. Cheraghipour K, Masoori L, Ezzatkhah F, SalimikiaI, Amiri S, Makenali AS, et al. Effect of chitosan onToxoplasma gondii infection: A systematic review.Parasite Epidemiol Control 2020;11: e00189. [DOI:10.1016/j.parepi.2020.e00189] [PMID] [PMCID]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Studies in Medical Sciences

Designed & Developed by : Yektaweb